OBJECTIVES: Identification of risk factors for Alzheimer disease (AD) is critical for establishing effective diagnostic and therapeutic strategies. Carrying the ε4 allele of the apolipoprotein E gene (APOE4) and having a family history of the disease are two such factors, with family history risk reflecting additional yet unknown or rarely studied genetic and perhaps nongenetic risks. Our aim was to determine the influence of APOE genotype and family history status on cognitive performance in healthy individuals. DESIGN: Longitudinal study. SETTING: Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles. PARTICIPANTS: Seventy-two cognitively healthy middle-aged and older people (mean age ± SD: 62 ± 9 years). MEASUREMENTS: Neuropsychological examinations at baseline and after 2 years. RESULTS: Subjects with a family history of AD had lower baseline scores in processing speed, executive functioning, memory encoding, and delayed memory when compared with those without a family history. The family history risk factor did not influence degree of cognitive decline over time. By contrast, baseline cognitive performance did not vary according to APOE4 carrier status. Non-APOE4 carriers showed improved cognitive performance in the memory domains at follow-up, while performance of APOE4 carriers did not change. CONCLUSIONS: Our data highlight the unique contributions of each risk factor to cognitive performance in healthy people. Both factors should be modeled in neuropsychological assessments of people at risk for AD.
OBJECTIVES: Identification of risk factors for Alzheimer disease (AD) is critical for establishing effective diagnostic and therapeutic strategies. Carrying the ε4 allele of the apolipoprotein E gene (APOE4) and having a family history of the disease are two such factors, with family history risk reflecting additional yet unknown or rarely studied genetic and perhaps nongenetic risks. Our aim was to determine the influence of APOE genotype and family history status on cognitive performance in healthy individuals. DESIGN: Longitudinal study. SETTING: Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles. PARTICIPANTS: Seventy-two cognitively healthy middle-aged and older people (mean age ± SD: 62 ± 9 years). MEASUREMENTS: Neuropsychological examinations at baseline and after 2 years. RESULTS: Subjects with a family history of AD had lower baseline scores in processing speed, executive functioning, memory encoding, and delayed memory when compared with those without a family history. The family history risk factor did not influence degree of cognitive decline over time. By contrast, baseline cognitive performance did not vary according to APOE4 carrier status. Non-APOE4 carriers showed improved cognitive performance in the memory domains at follow-up, while performance of APOE4 carriers did not change. CONCLUSIONS: Our data highlight the unique contributions of each risk factor to cognitive performance in healthy people. Both factors should be modeled in neuropsychological assessments of people at risk for AD.
Authors: Eric van Exel; Piet Eikelenboom; Hannie Comijs; Marijke Frölich; Johannes H Smit; Max L Stek; Philip Scheltens; Jan E Eefsting; Rudi G J Westendorp Journal: Arch Gen Psychiatry Date: 2009-11
Authors: Markus Donix; Alison C Burggren; Nanthia A Suthana; Prabha Siddarth; Arne D Ekstrom; Allison K Krupa; Michael Jones; Laurel Martin-Harris; Linda M Ercoli; Karen J Miller; Gary W Small; Susan Y Bookheimer Journal: Am J Psychiatry Date: 2010-08-04 Impact factor: 18.112
Authors: Kathleen M Hayden; Peter P Zandi; Nancy A West; Joann T Tschanz; Maria C Norton; Chris Corcoran; John C S Breitner; Kathleen A Welsh-Bohmer Journal: Arch Neurol Date: 2009-11
Authors: Antoinette E Zehnder; Stefan Bläsi; Manfred Berres; Andreas U Monsch; Hannes B Stähelin; René Spiegel Journal: Int J Geriatr Psychiatry Date: 2009-02 Impact factor: 3.485
Authors: P Kochunov; T Coyle; J Lancaster; D A Robin; J Hardies; V Kochunov; G Bartzokis; J Stanley; D Royall; A E Schlosser; M Null; P T Fox Journal: Neuroimage Date: 2009-09-28 Impact factor: 6.556
Authors: Kevin Duff; Leigh J Beglinger; David J Moser; Susan K Schultz; Jane S Paulsen Journal: Am J Geriatr Psychiatry Date: 2010-01 Impact factor: 4.105
Authors: Alison C Burggren; Zanjbeel Mahmood; Theresa M Harrison; Prabha Siddarth; Karen J Miller; Gary W Small; David A Merrill; Susan Y Bookheimer Journal: Alzheimers Dement Date: 2017-02-07 Impact factor: 21.566
Authors: Andrew J Aschenbrenner; David A Balota; Brian A Gordon; Roger Ratcliff; John C Morris Journal: Neuropsychology Date: 2016-02 Impact factor: 3.295
Authors: Erin M Jonaitis; Rebecca L Koscik; Asenath La Rue; Sterling C Johnson; Bruce P Hermann; Mark A Sager Journal: Clin Neuropsychol Date: 2015-05-27 Impact factor: 3.535
Authors: Alison C Burggren; Prabha Siddarth; Zanjbeel Mahmood; Edythe D London; Theresa M Harrison; David A Merrill; Gary W Small; Susan Y Bookheimer Journal: Cannabis Cannabinoid Res Date: 2018-12-10
Authors: Gonzalo Sánchez-Benavides; Juan D Gispert; Karine Fauria; José Luis Molinuevo; Nina Gramunt Journal: Alzheimers Dement (Amst) Date: 2016-08-30